Li Zhang


Country: China


  1. Zhang Y, Zhang Y, Zhang L. Expression of cancer-testis antigens in esophageal cancer and their progress in immunotherapy. J Cancer Res Clin Oncol. 2019;: pubmed publisher
    ..In this review, we summarize expression and prognostic value of MAGE-A, NY-ESO-1, LAGE-1, and TTK in esophageal cancer and point out recent advances in immunotherapy about them. ..
  2. Yuan J, Li B, Zhang N, Zhu H, Zhou L, Zhang L, et al. Clinical Implications of the BIM Deletion Polymorphism in Advanced Lung Adenocarcinoma Treated With Gefitinib. Clin Lung Cancer. 2018;19:e431-e438 pubmed publisher
    ..Our results indicate that the BIM deletion polymorphism might be a promising germline biomarker for gefitinib treatment in Chinese patients with lung adenocarcinoma. ..